Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction.

 

News | July 10, 2014

July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and...

Elixir Medical Corp. DESolve 100 CE mark
Feature | May 13, 2014

May 13, 2014 — Elixir Medical Corp. received European CE mark approval for its DESolve 100 Novolimus-eluting...

Feature | April 16, 2014

April 16, 2014 — Abbott announced it has completed enrollment of three...

Videos | Stents Bioresorbable | April 03, 2014

Bioresorbable stent technology was one of the big interventional technologies discussed at the American College of...

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent
Feature | March 31, 2014

March 31, 2014 — Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with...

News | March 12, 2014

March 12, 2014 — Micell Technologies Inc. announced that imaging and clinical results from the DESSOLVE I and...

Espirt Bioresorbable Vascular Scaffold BVS Peripheral Artery Disease PAD
News | January 23, 2014

January 23, 2014 – Six-month results of the ESPRIT trial suggest a...

Reva Medical ReZolve2 Bioresorbable Scaffold Stent Clinical Trial
News | January 23, 2014
January 23, 2014 — An implant of the ReZolve2 ...
Elixir Medical DESolve Bioresorbable Coronary Scaffold System Stents
News | January 22, 2014
January 22, 2014 — The first commercial implant of Elixir Medical’s CE Mark-approved DESolve Novolimus Eluting Coronary...
cath lab stents bioresorbable amaranth fortitude scaffold
Feature | January 14, 2014
January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The...
ACC, iPad cardiology apps
Feature | January 03, 2014 | Dave Fornell
DAIC readers chose the following stories as the most popular content in 2013, based on website analytics. The list is...
stents bioresorbable cath lab intravascular imaging clinical trial study abbott
Feature | November 07, 2013
November 7, 2013 — The Cardiovascular Research Foundation (CRF) and the Uppsala Clinical Research Center (UCR) of...
Feature | November 01, 2013
November 1, 2013 — A study found that both...
stents bioresorbable fortitude amaranth
News | October 31, 2013
October 31, 2013 — Amaranth Medical presented positive six-month angiographic results from its first-in-human...
News | October 23, 2013

October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to...

Overlay Init